A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study

Blood

Volumn 88, Issue 8, 1996, Pages 2841-2851

  Weick, James K ^a   Kopecky, Kenneth J ^a   Appelbaum, Frederick R ^a   Head, David R ^a   Kingsbury, Laura L ^a   Balcerzak, Stanley P ^a   Bickers, John N ^a   Hynes, H E ^a   Welborn, Jeanna L ^a   Simon, Sheryl R ^a   Grever, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 10244249096     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.8.2841.bloodjournal8882841     Document Type: Article

References (35)

1. Champlin R, Gale R: Acute myelogenous leukemia: Recent advances in therapy. Blood 69:1551, 1987
2. Bennett J, Anderson J, Cassileth P: Long term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group (ECOG) experience. Leuk Res 16:223, 1991
3. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK: Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 58:1203, 1981
4. Mayer RJ, Davis RB, Schiffer CA. Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E III: Intensive post-remission therapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896, 1994
5. Bloomfield C: Post-remission therapy in acute myeloid leukemia. J Clin Oncol 3:1570, 1987
6. Capizzi RL, Poole M, Cooper MR, Richards F II, Stuart JJ, Jackson DV Jr, White DR, Spurr CL, Hopkins JO, Muss HB: Treatment of poor risk acute leukemia with sequential high-dose Ara-C and asparaginase. Blood 63:694, 1984
7. Curtis JE, Messner HA, Minden MD, Minkin S, McCulloch EA: High dose cytosine arabinoside (ara-c) in the treatment of acute myelogenous leukemia: Contributions to outcome of clinical and laboratory attributes. J Clin Oncol 5:532, 1987
8. Hines JD, Mazza JJ, Oken MM, Bennett JM, Adelstein DJ, Keller A, O'Connell MJ: High-dose cytosine arabinoside and m-AMSA induction and consolidation in patients with previously untreated de novo acute non-lymphocytic leukemia: A phase I pilot study for the Eastern Cooperative Oncology Group. Semin Oncol 12:117, 1985
9. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP: High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62:361, 1983
10. Phillips GL, Reece DE, Shepherd JD, Barnett MJ, Brown RA, Frei-Lahr DA, Klingemann HG, Bolwell BJ, Spinelli JJ, Herzig RH: High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 77:1429, 1991
11. Geller RB, Burke PJ, Karp JE, Humphrey RL, Braine HG, Tucker RW, Fox MG, Zahurak M, Morrell L, Hall KL: A two-step timed sequential treatment for acute myelocytic leukemia. Blood 74:1499, 1989
12. Forman SJ, Nademanee AP, O'Donnell MR, Fahey JL, Snyder DS. Farbstein MJ, Lazar GS, DuBois NJ, Blume KG: High dose cytosine arabinoside and daunorubicin as primary therapy for adults with acute nonlymphoblastic leukemia: A pilot study. Semin Oncol 12:114, 1985
13. Harousseau JL, Milpied N, Briere J, Desablens B, Leprise PY, Ifrah N, Gandhour B, Casassus P: Double intensive consolidation chemotherapy in adult acute myeloid leukemia. J Clin Oncol 9:1432, 1991
14. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connell MJ: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924, 1992
15. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP: High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term followup and results. J Clin Oncol 7:1260, 1989
16. Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD: Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 62:315, 1983
17. Preisler HD, Raza A, Early A, Kirshner J, Brecher M, Greeman A. Rustum Y, Azarnia N, Priore R, Sandberg A: Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 5:722, 1987
18. Tricot G, Boogaerts MA, Vlietinck R, Emonds MP, Verwilghen RL: The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukemia. Br J Haematol 66:37, 1987
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
20. Cox DR: Analysis of Binary Data. London, England, Chapman & Hall, 1970
21. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187, 1972
22. Weick J, Kopecky K. Appelbaum F, Head D, Elias L, Kingsbury L, Daniels D, Balcerzak SP, Mills GM, Hynes HE: A randomized investigation of high dose (HDAC) versus standard dose (SDAC) cytosine arabinoside with daunorubicin (DNR) in patients with acute myelogenous leukemia. Proc Am Soc Clin Oncol 11:A856, 1992 (abstr)
23. Preisler H, Davis RB, Krishner J, Dupre E, Richards F III, Hoagland HC, Kopel S, Levy RN, Schulman P: Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study. Blood 69:1441, 1987
24. Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre OR, Schiffer C: A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood 78:2520, 1991
25. Vaughan W, Karp J, Burke P: Two cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 64:975, 1984
26. Omura G, Voeler W, and Lefante J: Treatment of acute myelogenous leukemia: Influence of the induction regimens and maintenance with chemotherapy or BCG immunotherapy. Cancer 49:1530, 1982
27. Sauter C, Berchtold W, Fopp M, Gratwohl A, Imbach P, Maurice P, Tschopp L, von Fliedner V, Cavalli F: Acute myelogenous leukemia: Maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet 1:379, 1984
28. Rudnick S, Cadman E, Capizzi R: High-dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 44:1189, 1979
29. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, and Antin J: Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 13:560, 1995
30. Bishop JF, Young GA, Szer J, Matthews JP, Page A: Randomized trial of high dose cytosine arabinoside (ARA-C) combination in induction in acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 11:A849, 1992 (abstr)
31. Wolff S, Marion J, Stein R: High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: A pilot study. Blood 65:1407, 1985
32. Schiller G, Gajewski J, Territo M: Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 80:2977, 1992
33. Preisler HD, Epstein J, Barcos M, Priore R, Raza A, Browman GP, Vogler R, Winton E, Grunwald H, Rai K: Prediction of response of nonlymphocytic leukemia to therapy with high-dose cytosine arabinoside. Br J Haematol 58:19, 1984
34. Fopp M, Schatzmann E, Fey MF, Gmuer J, Gratwohl A, Jacky E, Schmid L, Tichelli A, Tschopp L, Von Fliedner V: Randomized trial of post-remission high-dose (HIDAC) versus standard-dose (SDAC) cytosine arabinoside in adult acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 12:A999, 1993 (abstr)
35. Willman CL, Kopecky KJ, Weick J, Appelbaum F, Grever MR, Head Dr, Elias L, Balcerzak SP, Mills GM, Hynes HE: Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistant (MDR) gene expression, is associated with a decreased complete remission (CR) rate and CD34+ patients more frequently achieve cr with high-dose cytosine arabinoside. Proc Am Soc Clin Oncol 11:A857, 1992